Problems With Large Joints: Foreword.

FP Essent

Department of Family Medicine Rush Medical College Rush University, 630 S. Hermitage Ave Suite 605, Chicago, IL 60612.

Published: July 2016

Download full-text PDF

Source

Publication Analysis

Top Keywords

problems large
4
large joints
4
joints foreword
4
problems
1
joints
1
foreword
1

Similar Publications

Aligning genomes into common coordinates is central to pangenome analysis and construction, but it is also computationally expensive. Multi-sequence maximal unique matches (multi-MUMs) are guideposts for core genome alignments, helping to frame and solve the multiple alignment problem. We introduce Mumemto, a tool that computes multi-MUMs and other match types across large pangenomes.

View Article and Find Full Text PDF

Distraction osteogenesis is a valuable clinical technique used to address length discrepancies in long bone deformities. This procedure involves performing an osteotomy at an appropriate site in the bone and correcting the deformity through an extension system. This research aims to investigate the efficacy of a newly developed device for use in rat tibias and to provide an alternative to existing devices used in animal experiments.

View Article and Find Full Text PDF

Electrochemical CO reduction offers a promising method of converting renewable electrical energy into valuable hydrocarbon compounds vital to hard-to-abate sectors. Significant progress has been made on the lab scale, but scale-up demonstrations remain limited. Because of the low energy efficiency of CO reduction, we suspect that significant thermal gradients may develop in industrially relevant dimensions.

View Article and Find Full Text PDF

Artificial intelligence (AI) and machine learning (ML) are driving innovation in biosciences and are already affecting key elements of medical scholarship and clinical care. Many schools of medicine are capitalizing on the promise of these new technologies by establishing academic units to catalyze and grow research and innovation in AI/ML. At Stanford University, we have developed a successful model for an AI/ML research center with support from academic leaders, clinical departments, extramural grants, and industry partners.

View Article and Find Full Text PDF

Emerging oral therapeutic strategies for inhibiting PCSK9.

Atheroscler Plus

March 2025

Department of Pharmaceutical and Pharmacological Sciences, Padova, Italy.

Pharmacological inhibition of Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) have been firmly established to be an effective approach to reduce low-density lipoprotein (LDL) cholesterol levels and cardiovascular events. Subcutaneous administration of monoclonal antibodies (evolocumab and alirocumab) every 2 or 4 weeks determined a 60 % reduction of LDL cholesterol levels, while the GalNac-siRNA anti PCSK9 (inclisiran) provided an effective lipid lowering activity (-50 %) after an initial subcutaneous dose, repeated after 3 months and followed by a maintenance dose every 6 months. Although these two approaches have the potentiality to bring the majority of patients at high and very-high cardiovascular risk to the appropriate LDL cholesterol targets, their cost and subcutaneous administration represent a strong limitation for their large-scale use.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!